Instrument, Consumables Sales Drive NanoString's Q2 Revenues up 51 Percent | GenomeWeb

NEW YORK (GenomeWeb) – NanoString Technologies reported after the close of the market Tuesday that its second quarter revenues increased 51 percent year over year.

Shares in NanoString fell in Wednesday morning trade, however, on concerns about reimbursement for its Prosigna test.

The Seattle-based molecular diagnostics firm brought in total revenues of $10.9 million for the three months ended June 30, up from $7.2 million in the second quarter of 2013. It beat the average Wall Street estimate of $10.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.